Prevalence of dyslipidemia, treatment rate and its control among patients with type 2 diabetes mellitus in Northwest China: a cross-sectional study

Background The prevalence of cardiovascular disease (CVD) is high in China, especially in Northwest China, and dyslipidemia in diabetes is a major factor at risk for CVD. The dyslipidemia prevalence, treatment and control among type 2 diabetes mellitus (T2DM) patients in Northwest China were investi...

Full description

Saved in:
Bibliographic Details
Published inLipids in health and disease Vol. 21; no. 1; pp. 1 - 9
Main Authors Li, Jiahang, Nie, Zhenxing, Ge, Zhongli, Shi, Lei, Gao, Bin, Yang, Yan
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 25.08.2022
BioMed Central
BMC
Subjects
Age
Body mass index
Cardiovascular disease
Cardiovascular diseases
Care and treatment
Cholesterol
Chronic illnesses
Complications and side effects
Control
Cross-sectional studies
Developing countries
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetic retinopathy
Dyslipidemia
Dyslipidemias
Hemoglobin
High density lipoprotein
Hypertension
LDCs
Lipids
Low density lipoprotein
Medical records
Metabolic disorders
Patients
Prevalence
Risk factors
Statins
Treatment
Type 2 diabetes
Type 2 diabetes mellitus
China
Online AccessGet full text

Cover

Abstract Background The prevalence of cardiovascular disease (CVD) is high in China, especially in Northwest China, and dyslipidemia in diabetes is a major factor at risk for CVD. The dyslipidemia prevalence, treatment and control among type 2 diabetes mellitus (T2DM) patients in Northwest China were investigated. Methods In the cross-sectional retrospective research, 1386 medical records of T2DM patients were collected from the Endocrine Department of Tangdu Hospital. And patients' age, sex, diabetes duration, glycated hemoglobin (HbA1c), complications, lipid levels, and drug use were recorded. The patient characteristics, lipid level and lipid-lowering therapy were analyzed. Results In this study, the dyslipidemia prevalence among T2DM patients was 87.7%, the treatment rate was 68.0%. The overall control rate of low-density lipoprotein cholesterol (LDL-C) was 43.1%, and control rates reached 52.7% for high-risk subjects and 36.1% for very high-risk subjects. The overall control rate of non-high-density lipoprotein cholesterol (non-HDL-C) was 19.8%. HbA1c (%) [greater than or equal to] 7 was indicated as a major factor predicting failure of LDL-C and non-HDL-C control [odds ratio (OR) 1.521; 2.206, 95% confidence interval (CI) 1.154-2.005; 1.583-3.076)]. Conclusion Among patients with T2DM, it is high prevalence of dyslipidemia and low rate of treatment and control, and higher HbA1c level is the main factor for poor lipid control. It calls for more efforts to promote early screening, prevention and treatment of dyslipidemia for patients, thereby reducing the risk of CVD. Keywords: Dyslipidemia, Prevalence, Treatment, Control, Type 2 diabetes mellitus
AbstractList The prevalence of cardiovascular disease (CVD) is high in China, especially in Northwest China, and dyslipidemia in diabetes is a major factor at risk for CVD. The dyslipidemia prevalence, treatment and control among type 2 diabetes mellitus (T2DM) patients in Northwest China were investigated. In the cross-sectional retrospective research, 1386 medical records of T2DM patients were collected from the Endocrine Department of Tangdu Hospital. And patients' age, sex, diabetes duration, glycated hemoglobin (HbA1c), complications, lipid levels, and drug use were recorded. The patient characteristics, lipid level and lipid-lowering therapy were analyzed. In this study, the dyslipidemia prevalence among T2DM patients was 87.7%, the treatment rate was 68.0%. The overall control rate of low-density lipoprotein cholesterol (LDL-C) was 43.1%, and control rates reached 52.7% for high-risk subjects and 36.1% for very high-risk subjects. The overall control rate of non-high-density lipoprotein cholesterol (non-HDL-C) was 19.8%. HbA1c (%) [greater than or equal to] 7 was indicated as a major factor predicting failure of LDL-C and non-HDL-C control [odds ratio (OR) 1.521; 2.206, 95% confidence interval (CI) 1.154-2.005; 1.583-3.076)]. Among patients with T2DM, it is high prevalence of dyslipidemia and low rate of treatment and control, and higher HbA1c level is the main factor for poor lipid control. It calls for more efforts to promote early screening, prevention and treatment of dyslipidemia for patients, thereby reducing the risk of CVD.
Abstract Background The prevalence of cardiovascular disease (CVD) is high in China, especially in Northwest China, and dyslipidemia in diabetes is a major factor at risk for CVD. The dyslipidemia prevalence, treatment and control among type 2 diabetes mellitus (T2DM) patients in Northwest China were investigated. Methods In the cross-sectional retrospective research, 1386 medical records of T2DM patients were collected from the Endocrine Department of Tangdu Hospital. And patients’ age, sex, diabetes duration, glycated hemoglobin (HbA1c), complications, lipid levels, and drug use were recorded. The patient characteristics, lipid level and lipid-lowering therapy were analyzed. Results In this study, the dyslipidemia prevalence among T2DM patients was 87.7%, the treatment rate was 68.0%. The overall control rate of low-density lipoprotein cholesterol (LDL-C) was 43.1%, and control rates reached 52.7% for high-risk subjects and 36.1% for very high-risk subjects. The overall control rate of non-high-density lipoprotein cholesterol (non-HDL-C) was 19.8%. HbA1c (%) ≥ 7 was indicated as a major factor predicting failure of LDL-C and non-HDL-C control [odds ratio (OR) 1.521; 2.206, 95% confidence interval (CI) 1.154–2.005; 1.583–3.076)]. Conclusion Among patients with T2DM, it is high prevalence of dyslipidemia and low rate of treatment and control, and higher HbA1c level is the main factor for poor lipid control. It calls for more efforts to promote early screening, prevention and treatment of dyslipidemia for patients, thereby reducing the risk of CVD.
Background The prevalence of cardiovascular disease (CVD) is high in China, especially in Northwest China, and dyslipidemia in diabetes is a major factor at risk for CVD. The dyslipidemia prevalence, treatment and control among type 2 diabetes mellitus (T2DM) patients in Northwest China were investigated. Methods In the cross-sectional retrospective research, 1386 medical records of T2DM patients were collected from the Endocrine Department of Tangdu Hospital. And patients’ age, sex, diabetes duration, glycated hemoglobin (HbA1c), complications, lipid levels, and drug use were recorded. The patient characteristics, lipid level and lipid-lowering therapy were analyzed. Results In this study, the dyslipidemia prevalence among T2DM patients was 87.7%, the treatment rate was 68.0%. The overall control rate of low-density lipoprotein cholesterol (LDL-C) was 43.1%, and control rates reached 52.7% for high-risk subjects and 36.1% for very high-risk subjects. The overall control rate of non-high-density lipoprotein cholesterol (non-HDL-C) was 19.8%. HbA1c (%) ≥ 7 was indicated as a major factor predicting failure of LDL-C and non-HDL-C control [odds ratio (OR) 1.521; 2.206, 95% confidence interval (CI) 1.154–2.005; 1.583–3.076)]. Conclusion Among patients with T2DM, it is high prevalence of dyslipidemia and low rate of treatment and control, and higher HbA1c level is the main factor for poor lipid control. It calls for more efforts to promote early screening, prevention and treatment of dyslipidemia for patients, thereby reducing the risk of CVD.
Background The prevalence of cardiovascular disease (CVD) is high in China, especially in Northwest China, and dyslipidemia in diabetes is a major factor at risk for CVD. The dyslipidemia prevalence, treatment and control among type 2 diabetes mellitus (T2DM) patients in Northwest China were investigated. Methods In the cross-sectional retrospective research, 1386 medical records of T2DM patients were collected from the Endocrine Department of Tangdu Hospital. And patients' age, sex, diabetes duration, glycated hemoglobin (HbA1c), complications, lipid levels, and drug use were recorded. The patient characteristics, lipid level and lipid-lowering therapy were analyzed. Results In this study, the dyslipidemia prevalence among T2DM patients was 87.7%, the treatment rate was 68.0%. The overall control rate of low-density lipoprotein cholesterol (LDL-C) was 43.1%, and control rates reached 52.7% for high-risk subjects and 36.1% for very high-risk subjects. The overall control rate of non-high-density lipoprotein cholesterol (non-HDL-C) was 19.8%. HbA1c (%) [greater than or equal to] 7 was indicated as a major factor predicting failure of LDL-C and non-HDL-C control [odds ratio (OR) 1.521; 2.206, 95% confidence interval (CI) 1.154-2.005; 1.583-3.076)]. Conclusion Among patients with T2DM, it is high prevalence of dyslipidemia and low rate of treatment and control, and higher HbA1c level is the main factor for poor lipid control. It calls for more efforts to promote early screening, prevention and treatment of dyslipidemia for patients, thereby reducing the risk of CVD. Keywords: Dyslipidemia, Prevalence, Treatment, Control, Type 2 diabetes mellitus
The prevalence of cardiovascular disease (CVD) is high in China, especially in Northwest China, and dyslipidemia in diabetes is a major factor at risk for CVD. The dyslipidemia prevalence, treatment and control among type 2 diabetes mellitus (T2DM) patients in Northwest China were investigated.BACKGROUNDThe prevalence of cardiovascular disease (CVD) is high in China, especially in Northwest China, and dyslipidemia in diabetes is a major factor at risk for CVD. The dyslipidemia prevalence, treatment and control among type 2 diabetes mellitus (T2DM) patients in Northwest China were investigated.In the cross-sectional retrospective research, 1386 medical records of T2DM patients were collected from the Endocrine Department of Tangdu Hospital. And patients' age, sex, diabetes duration, glycated hemoglobin (HbA1c), complications, lipid levels, and drug use were recorded. The patient characteristics, lipid level and lipid-lowering therapy were analyzed.METHODSIn the cross-sectional retrospective research, 1386 medical records of T2DM patients were collected from the Endocrine Department of Tangdu Hospital. And patients' age, sex, diabetes duration, glycated hemoglobin (HbA1c), complications, lipid levels, and drug use were recorded. The patient characteristics, lipid level and lipid-lowering therapy were analyzed.In this study, the dyslipidemia prevalence among T2DM patients was 87.7%, the treatment rate was 68.0%. The overall control rate of low-density lipoprotein cholesterol (LDL-C) was 43.1%, and control rates reached 52.7% for high-risk subjects and 36.1% for very high-risk subjects. The overall control rate of non-high-density lipoprotein cholesterol (non-HDL-C) was 19.8%. HbA1c (%) ≥ 7 was indicated as a major factor predicting failure of LDL-C and non-HDL-C control [odds ratio (OR) 1.521; 2.206, 95% confidence interval (CI) 1.154-2.005; 1.583-3.076)].RESULTSIn this study, the dyslipidemia prevalence among T2DM patients was 87.7%, the treatment rate was 68.0%. The overall control rate of low-density lipoprotein cholesterol (LDL-C) was 43.1%, and control rates reached 52.7% for high-risk subjects and 36.1% for very high-risk subjects. The overall control rate of non-high-density lipoprotein cholesterol (non-HDL-C) was 19.8%. HbA1c (%) ≥ 7 was indicated as a major factor predicting failure of LDL-C and non-HDL-C control [odds ratio (OR) 1.521; 2.206, 95% confidence interval (CI) 1.154-2.005; 1.583-3.076)].Among patients with T2DM, it is high prevalence of dyslipidemia and low rate of treatment and control, and higher HbA1c level is the main factor for poor lipid control. It calls for more efforts to promote early screening, prevention and treatment of dyslipidemia for patients, thereby reducing the risk of CVD.CONCLUSIONAmong patients with T2DM, it is high prevalence of dyslipidemia and low rate of treatment and control, and higher HbA1c level is the main factor for poor lipid control. It calls for more efforts to promote early screening, prevention and treatment of dyslipidemia for patients, thereby reducing the risk of CVD.
ArticleNumber 77
Audience Academic
Author Yang, Yan
Shi, Lei
Gao, Bin
Li, Jiahang
Nie, Zhenxing
Ge, Zhongli
Author_xml – sequence: 1
  givenname: Jiahang
  surname: Li
  fullname: Li, Jiahang
– sequence: 2
  givenname: Zhenxing
  surname: Nie
  fullname: Nie, Zhenxing
– sequence: 3
  givenname: Zhongli
  surname: Ge
  fullname: Ge, Zhongli
– sequence: 4
  givenname: Lei
  surname: Shi
  fullname: Shi, Lei
– sequence: 5
  givenname: Bin
  surname: Gao
  fullname: Gao, Bin
– sequence: 6
  givenname: Yan
  surname: Yang
  fullname: Yang, Yan
BookMark eNp9UsuO1DAQjNAi9gE_wMkSFw5ksR3HiTkgrUY8VloBB5C4WR2nM-NRYg-2Z1fzHfwwzswKmBVCPrhlV1Xb1XVenDjvsCieM3rJWCtfR8aVECXlvKRMKlayR8UZE40sa8a-n_xVnxbnMa4p5bSR8klxWslct3V9Vvz8EvAWRnQGiR9Iv4uj3dgeJwuvSAoIaUKXSICEBFxPbIrEeJeCHwlM3i3JBpLNkEjubFqRtNsg4aS30GHCSCYcR5u2kVhHPvmQVncYE1msrIM3BIgJPsYyoknWOxhJTNt-97R4PMAY8dn9flF8e__u6-JjefP5w_Xi6qY0taCp7AbeNpLToZWAvOedaCpphlyxnlPZ857SCrrKIFMUmUTVGsiXrKk6VdOquiiuD7q9h7XeBDtB2GkPVu8PfFhqCMmaEbUQXKpWZtspF1jVHW1U2w8VMAUVa1TWenvQ2my7CXuTHQkwHoke3zi70kt_q5WgQlazwMt7geB_bLNJerLRZPfAod9GzRsqGyaFmt_94gF07bch2zejWF0zKWnzB7XM49XWDT73NbOovmqYUEIxVWfU5T9Qec0RyIPGwebzIwI_EPajCzj8_iOjeo6lPsRS51jqfSw1y6T2AcnYBPPMczc7_o_6C2Jm54c
CitedBy_id crossref_primary_10_1007_s00125_024_06142_3
crossref_primary_10_32388_T52NT9_2
crossref_primary_10_3390_jpm13101466
crossref_primary_10_1016_j_nutres_2022_12_008
crossref_primary_10_1007_s11255_023_03784_x
crossref_primary_10_1016_j_endmts_2023_100152
crossref_primary_10_1155_2024_2552658
crossref_primary_10_1097_MD_0000000000041061
crossref_primary_10_32388_T52NT9_5
crossref_primary_10_32388_T52NT9_4
crossref_primary_10_32388_T52NT9_3
crossref_primary_10_3389_fendo_2024_1367376
crossref_primary_10_1186_s12944_023_01873_5
crossref_primary_10_1007_s11239_023_02823_9
crossref_primary_10_2478_jtim_2024_0014
crossref_primary_10_1186_s12902_023_01522_z
crossref_primary_10_3389_fphys_2024_1464744
crossref_primary_10_3390_ph17020219
Cites_doi 10.1161/JAHA.118.010827
10.1038/s41569-018-0119-4
10.2147/DMSO.S283171
10.1111/jep.12095
10.1016/j.arteri.2013.12.001
10.1016/j.jacc.2021.02.030
10.11909/j.issn.1671-5411.2018.01.011
10.1038/s41586-019-1797-8
10.1007/s42000-018-0014-8
10.1016/j.dsx.2009.04.005
10.1186/s12902-021-00863-x
10.3949/ccjm.87a.19078
10.5551/jat.RV17023
10.1007/s00125-015-3525-8
10.1016/j.jacl.2015.10.009
10.3760/cma.j.cn112138-20211027-00751
10.1016/j.metabol.2014.08.010
10.3390/ijms21176275
10.1186/s12933-021-01400-9
10.1177/1741826711400545
10.1186/s12944-021-01455-3
10.1177/2042018817692296
10.1016/j.ahj.2018.12.007
10.1161/CIRCULATIONAHA.108.108.768986
ContentType Journal Article
Copyright COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022. The Author(s).
The Author(s) 2022
Copyright_xml – notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022. The Author(s).
– notice: The Author(s) 2022
DBID AAYXX
CITATION
3V.
7X7
7XB
88E
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
RC3
7X8
5PM
DOA
DOI 10.1186/s12944-022-01691-1
DatabaseName CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central
Engineering Research Database
ProQuest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1476-511X
EndPage 9
ExternalDocumentID oai_doaj_org_article_4426986118024e35b0798df3a19a3179
PMC9404639
A714949195
10_1186_s12944_022_01691_1
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: ;
GroupedDBID ---
0R~
29L
2WC
53G
5GY
5VS
7X7
88E
8FE
8FH
8FI
8FJ
A8Z
AAFWJ
AAHBH
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
IAO
IGS
IHR
INH
INR
ITC
KQ8
LK8
M1P
M48
M7P
M~E
O5R
O5S
OK1
OVT
P2P
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
PMFND
3V.
7XB
8FD
8FK
AZQEC
DWQXO
FR3
GNUQQ
K9.
P64
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
RC3
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c540t-bf287620f86ae2d2b4736cf2d21d206d2d003ab3ce190e16e98cad21173b95033
IEDL.DBID M48
ISSN 1476-511X
IngestDate Wed Aug 27 01:32:04 EDT 2025
Thu Aug 21 18:11:03 EDT 2025
Fri Jul 11 12:02:36 EDT 2025
Fri Jul 25 19:27:01 EDT 2025
Tue Jun 17 21:48:22 EDT 2025
Tue Jun 10 20:39:25 EDT 2025
Tue Jul 01 00:23:18 EDT 2025
Thu Apr 24 23:07:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-bf287620f86ae2d2b4736cf2d21d206d2d003ab3ce190e16e98cad21173b95033
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/2715516607?pq-origsite=%requestingapplication%
PMID 36002855
PQID 2715516607
PQPubID 42587
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_4426986118024e35b0798df3a19a3179
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9404639
proquest_miscellaneous_2706716493
proquest_journals_2715516607
gale_infotracmisc_A714949195
gale_infotracacademiconefile_A714949195
crossref_primary_10_1186_s12944_022_01691_1
crossref_citationtrail_10_1186_s12944_022_01691_1
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-08-25
PublicationDateYYYYMMDD 2022-08-25
PublicationDate_xml – month: 08
  year: 2022
  text: 2022-08-25
  day: 25
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Lipids in health and disease
PublicationYear 2022
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References K Haile (1691_CR13) 2020; 13
A Hussain (1691_CR22) 2017; 8
AK Gitt (1691_CR20) 2012; 19
VG Athyros (1691_CR8) 2018; 17
M Roden (1691_CR2) 2019; 576
T Hirano (1691_CR14) 2018; 25
RM Parikh (1691_CR11) 2010; 4
D Giugliano (1691_CR4) 2021; 20
SJ Kim (1691_CR17) 2021; 20
L Wu (1691_CR15) 2014; 63
CD Society (1691_CR3) 2022; 61
B Verges (1691_CR7) 2015; 58
C Reiter-Brennan (1691_CR16) 2020; 87
G Henock (1691_CR18) 2019; 210
L Yan (1691_CR6) 2016; 10
A Begum (1691_CR23) 2019; 28
R Huang (1691_CR21) 2021; 21
D Zhao (1691_CR9) 2019; 16
U Galicia-Garcia (1691_CR1) 2020; 21
S Martinez-Hervas (1691_CR12) 2014; 26
PM Ho (1691_CR24) 2009; 119
L Vogt (1691_CR19) 2019; 8
K Ladova (1691_CR25) 2014; 20
GR Chujunren (1691_CR10) 2018; 15
I Cavallari (1691_CR5) 2021; 77
References_xml – volume: 8
  start-page: e010827
  issue: 9
  year: 2019
  ident: 1691_CR19
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.118.010827
– volume: 16
  start-page: 203
  issue: 4
  year: 2019
  ident: 1691_CR9
  publication-title: Nat Rev Cardiol
  doi: 10.1038/s41569-018-0119-4
– volume: 28
  start-page: 91
  issue: 1
  year: 2019
  ident: 1691_CR23
  publication-title: Mymensingh Med J
– volume: 13
  start-page: 4589
  year: 2020
  ident: 1691_CR13
  publication-title: Southwest Ethiopia Diabetes Metab Syndr Obes
  doi: 10.2147/DMSO.S283171
– volume: 20
  start-page: 111
  issue: 2
  year: 2014
  ident: 1691_CR25
  publication-title: J Eval Clin Pract.
  doi: 10.1111/jep.12095
– volume: 26
  start-page: 107
  issue: 3
  year: 2014
  ident: 1691_CR12
  publication-title: Clin Investig Arterioscler.
  doi: 10.1016/j.arteri.2013.12.001
– volume: 77
  start-page: 1837
  issue: 14
  year: 2021
  ident: 1691_CR5
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2021.02.030
– volume: 15
  start-page: 1
  issue: 1
  year: 2018
  ident: 1691_CR10
  publication-title: Chin J Cardiol.
  doi: 10.11909/j.issn.1671-5411.2018.01.011
– volume: 576
  start-page: 51
  issue: 7785
  year: 2019
  ident: 1691_CR2
  publication-title: Nature
  doi: 10.1038/s41586-019-1797-8
– volume: 17
  start-page: 61
  issue: 1
  year: 2018
  ident: 1691_CR8
  publication-title: Hormones (Athens).
  doi: 10.1007/s42000-018-0014-8
– volume: 4
  start-page: 10
  issue: 1
  year: 2010
  ident: 1691_CR11
  publication-title: Diabetes Metab Syndr
  doi: 10.1016/j.dsx.2009.04.005
– volume: 21
  start-page: 198
  issue: 1
  year: 2021
  ident: 1691_CR21
  publication-title: BMC Endocr Disord
  doi: 10.1186/s12902-021-00863-x
– volume: 87
  start-page: 231
  issue: 4
  year: 2020
  ident: 1691_CR16
  publication-title: Cleve Clin J Med
  doi: 10.3949/ccjm.87a.19078
– volume: 25
  start-page: 771
  issue: 9
  year: 2018
  ident: 1691_CR14
  publication-title: J Atheroscler Thromb
  doi: 10.5551/jat.RV17023
– volume: 58
  start-page: 886
  issue: 5
  year: 2015
  ident: 1691_CR7
  publication-title: Diabetologia
  doi: 10.1007/s00125-015-3525-8
– volume: 10
  start-page: 150
  issue: 1
  year: 2016
  ident: 1691_CR6
  publication-title: J Clin Lipidol
  doi: 10.1016/j.jacl.2015.10.009
– volume: 61
  start-page: 12
  issue: 1
  year: 2022
  ident: 1691_CR3
  publication-title: Zhonghua Nei Ke Za Zhi
  doi: 10.3760/cma.j.cn112138-20211027-00751
– volume: 63
  start-page: 1469
  issue: 12
  year: 2014
  ident: 1691_CR15
  publication-title: Metabolism.
  doi: 10.1016/j.metabol.2014.08.010
– volume: 21
  start-page: 6275
  issue: 17
  year: 2020
  ident: 1691_CR1
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21176275
– volume: 20
  start-page: 205
  issue: 1
  year: 2021
  ident: 1691_CR4
  publication-title: Cardiovasc Diabetol
  doi: 10.1186/s12933-021-01400-9
– volume: 19
  start-page: 221
  issue: 2
  year: 2012
  ident: 1691_CR20
  publication-title: Eur J Prev Cardiol
  doi: 10.1177/1741826711400545
– volume: 20
  start-page: 29
  issue: 1
  year: 2021
  ident: 1691_CR17
  publication-title: Lipids Health Dis
  doi: 10.1186/s12944-021-01455-3
– volume: 8
  start-page: 51
  issue: 4
  year: 2017
  ident: 1691_CR22
  publication-title: Ther Adv Endocrinol Metab
  doi: 10.1177/2042018817692296
– volume: 210
  start-page: 18
  year: 2019
  ident: 1691_CR18
  publication-title: Curriculum in Cardiology.
  doi: 10.1016/j.ahj.2018.12.007
– volume: 119
  start-page: 3028
  issue: 23
  year: 2009
  ident: 1691_CR24
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.108.108.768986
SSID ssj0020766
Score 2.387111
Snippet Background The prevalence of cardiovascular disease (CVD) is high in China, especially in Northwest China, and dyslipidemia in diabetes is a major factor at...
The prevalence of cardiovascular disease (CVD) is high in China, especially in Northwest China, and dyslipidemia in diabetes is a major factor at risk for CVD....
Abstract Background The prevalence of cardiovascular disease (CVD) is high in China, especially in Northwest China, and dyslipidemia in diabetes is a major...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Age
Body mass index
Cardiovascular disease
Cardiovascular diseases
Care and treatment
Cholesterol
Chronic illnesses
Complications and side effects
Control
Cross-sectional studies
Developing countries
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetic retinopathy
Dyslipidemia
Dyslipidemias
Hemoglobin
High density lipoprotein
Hypertension
LDCs
Lipids
Low density lipoprotein
Medical records
Metabolic disorders
Patients
Prevalence
Risk factors
Statins
Treatment
Type 2 diabetes
Type 2 diabetes mellitus
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Pi9UwEA-yB_Eiuqv4dJURRA9atmnapPH2FJdFWE8u7C0kbYoP3L7F9h32c_iFnZmmj62CXryVJoEkM5k_ycxvhHgVO6saX4fMh8pmZYM2XFCqy3T0VTQqxq6i5OTzL_rsovx8WV3eKvVFMWETPPC0cScl5VrWmpHKyqiqkBtbt53y0nrUfZy6hzpvdqaSq4XeuZ5TZGp9MqBWK8uMItcJfURmcqGGGK3_T5n8e5zkLcVz-kDcTxYjrKeZPhR3Yn8ojtY9estXN_AaOIaTL8cPxd3z9FR-JH4SOJPnlCLYdtDeoEE5VYP172AfXg6EFAG-b2EzDpDi1oErEEGCXB2A7mqB7mqhgPmuFq4IyXPcDbDpgR9_CHMBuBz3e_DAy84GDvSi6TOM7SNxcfrp68ezLFVgyBq05MYsdAVJy7yrtY9FW4TSKN10-CXbItdt0aJQ8EE1Ee2KKHW0deOxURoVLD2QPhYH_baPTwSUsvXG-zx2ISJNpY_BB69NoSySr5YrIWeCuCbBk1OVjO-O3ZRau4mIDonomIgOx7zdj7mewDn-2vsD0Xnfk4C1-Qeym0vs5v7FbivxhrjE0fHH6TU-ZTHgIglIy62NJLwfaauVOF70xGPbLJtnPnNJbAyuMPxwqXOzEi_3zTSSQuH6uN1RHzQw0Mm1aiXMgj8XK1u29JtvDB1uS0KIs0__x1Y8E_cKPlEoaqtjcTD-2MXnaKGN4QUfxl_X7De_
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Pi9UwEA-6gngR3VWsrjKC6EHLvjRp0niRp7gswnpy4d1C0qb6wG3Xbd9hP4df2Jm89K1V2FtpEtowk8n8_Q1jr0JrRO0qnztfmlzWqMN5IdpcBVcGLUJoSypOPv2qTs7kl1W5Sg63IaVVTjIxCuqmr8lHflToGNNRC_3h4ldOXaMouppaaNxmdwi6jFK69Ora4EIbXU2FMpU6GvBukzKn_HXCIOE5n11GEbP_f8n8b7bkX9fP8QN2P-mNsNwS-iG7Fbp9drDs0GY-v4LXEDM5o4t8n909TQHzA_abIJpcLCyCvoXmCtXKbU9Y9w52SeZAeBHgugbW4wApex1iHyJIwKsDkMcWyGMLBUweWzgnPM9xM8C6gxgCIuQFiE2534ODuO18iOle9PsRzPYROzv-_O3TSZ76MOQ16nNj7tuCZOairZQLRVN4qYWqW3ziTbFQTdGgaHBe1AG1i8BVMFXtcJBr4Q2FSR-zva7vwhMGkjdOO7cIrQ9SFtwF77xTuhAGFZeKZ4xPBLF1AimnXhk_bTRWKmW3RLRIRBuJaHHN292aiy1Ex42zPxKddzMJXju-6C-_23RaraQC30pFeDwZROkX2lRNKxw3DhUuk7E3xCWWhAD-Xu1SLQNukuC07FJzQv1BlszY4WwmHt56PjzxmU3CY7DXrJ6xl7thWkkJcV3oNzQH1Qw0dY3ImJ7x52xn85Fu_SMCiBtJOHHm6c0ff8buFfGsoCgtD9neeLkJz1EDG_2LeMz-AB6wMVQ
  priority: 102
  providerName: ProQuest
Title Prevalence of dyslipidemia, treatment rate and its control among patients with type 2 diabetes mellitus in Northwest China: a cross-sectional study
URI https://www.proquest.com/docview/2715516607
https://www.proquest.com/docview/2706716493
https://pubmed.ncbi.nlm.nih.gov/PMC9404639
https://doaj.org/article/4426986118024e35b0798df3a19a3179
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1fixMxEA_nHYgvoneK1bOMIPqgq7ubbLIRRHpyx1HoIWqhbyHZzWrhbqvdFuzn8As7k-4WVw_Bp5YmKZudmWT-_oaxp77SvLC5i6zLdCQK1OEc51Ukvc284t5XGRUnTy7k-VSMZ9lsj3XtjtoX2Fxr2lE_qeny8tWP75t3KPBvg8Dn8nWDd5YQEeWlE7ZIEqE1dIA3kyJBnYhdVCFFm31bbaRkhIrGrCuiufY_ehdVwPP_-9T-M5Pyt6vp7A673eqUMNoywV225-tDdjSq0Z6-2sAzCFmewX1-yG5O2mD6EftJ8E02FB3BooJygyrntl-sfQm7BHQgLAmwdQnzVQNtZjuEHkXQgrI2QN5cIG8upNB5c-GKsD5X6wbmNYTwEKEyQGjY_QYshG1HTUgFo8cPQLf32PTs9PP786jt0RAVqOutIleldJ7GVS6tT8vUCcVlUeG3pExjWaYlHhvW8cKj5uET6XVeWBxMFHeaQqj32X69qP0DBiIprbI29pXzQqSJ9c46K1XKNSo1eTJgSUcQU7QA5tRH49IEQyaXZktEg0Q0gYgG17zYrfm2he_45-wTovNuJkFvhx8Wyy-mlWQjqPg3lwE6T3ieuVjpvKy4TbRFZUwP2HPiEkMsi49X2LbOATdJUFtmpBJCBEp0NmDHvZko2EV_uOMz08mFSVUIbcpYDdiT3TCtpGS52i_WNAdVEDSDNR8w1ePP3s76I_X8awAX14Iw5PTD_3pxj9itNIgOnrrZMdtfLdf-MSprKzdkN9RMDdnBaDT-NMbPk9OLDx-HwfUxDNL5C48bP0M
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJwEvCDYQhQFG4vIA0eJLnBgJoQ42dWytENqkvXl24kAllo6lFerv4H_wGznHTQoBaW97q2I7jXWOj8_1O4Q886UWuc1cZF2iI5mDDueEKCPlbeJT4X2ZYHHyaKyGx_LjSXKyRn61tTCYVtnKxCCoi2mOPvJtnoaYjorTd-ffI-wahdHVtoXGki0O_OIHmGz12_0PQN_nnO_tHr0fRk1XgSgH7WQWuZKjBIjLTFnPC-5kKlRewi9W8FgVvABGt07kHu5Kz5TXWW5hkKXCaQz6wXuvkXUpwJTpkfWd3fGnzysTL06VaktzMrVdw20qZYQZ84h6wiLWuf5Cl4D_74J_8zP_uvD2bpNbjaZKB0vWukPWfLVBNgcVWOlnC_qChtzR4JTfINdHTYh-k_xEUCgbSpnotKTFAhTZZRda-5qu0topIlRQWxV0Mqtpky9PQ-cj2kC91hR9xBR9xJTT1kdMzxBBdDav6aSiIeiEWA80tAF_Qy0N247qkGCGnx_gc--S4yuh0T3Sq6aVv0-oZIVNrY196byUnFnvrLMq5UKDqpSxPmEtQUzewKJjd45vJphHmTJLIhogoglENLDm1WrN-RIU5NLZO0jn1UwE9A4PphdfTCMfjMSS4kwFQD7pReLiVGdFKSzTFlQ83ScvkUsMih34vNw21ROwSQTwMoOUIc4Q00mfbHVmgrjIu8Mtn5lGXNXmz-Hqk6erYVyJKXiVn85xDig2YFxr0Sdphz87O-uOVJOvAbJcS0Sm0w8u__Mn5MbwaHRoDvfHBw_JTR7ODQjyZIv0Zhdz_wj0v5l73Bw6Sk6v-pz_BhEFbrc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevalence+of+dyslipidemia%2C+treatment+rate+and+its+control+among+patients+with+type+2+diabetes+mellitus+in+Northwest+China%3A+a+cross-sectional+study&rft.jtitle=Lipids+in+health+and+disease&rft.au=Li%2C+Jiahang&rft.au=Nie%2C+Zhenxing&rft.au=Ge%2C+Zhongli&rft.au=Shi%2C+Lei&rft.date=2022-08-25&rft.issn=1476-511X&rft.eissn=1476-511X&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12944-022-01691-1&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12944_022_01691_1
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-511X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-511X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-511X&client=summon